Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.
ENDRA Life Sciences’ TAEUS De Novo Submission Advances To Next Stage Of Review With FDA
ENDRA Life Sciences Inc.(NASDAQ:NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company's De Novo request for the TAEUS liver system has advanced to
